secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-115177
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha reports FY2025 net loss $109M; TSHA-102 pivotal trial dosing on track to complete Q2 2026
--------------------------------------------------------------------------------

- Net loss $109.0M ($0.34/share) vs $89.3M ($0.36) in 2024; R&D expenses rose to $86.4M.
- Cash $319.8M as of Dec 31, 2025; raised $50M via ATM in Q4; expects funding into 2028.
- Dosed multiple Rett patients in REVEAL pivotal trial; enrollment advancing, on track to complete dosing in Q2 2026.
- FDA cleared ASPIRE trial in patients aged 2 to <4 yrs; alignment on CMC and data pooling for BLA submission.
- TSHA-102 generally well tolerated; no treatment-related SAEs or DLTs as of March 2026 data cutoff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/0001193125-26-115177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-115177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer